Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib plus toripalimab versus approved first-line regimens for metastatic clear cell renal cell carcinoma
ChiCTR2400094340Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorolanib and toripalimab in clear cell renal cell carcinoma (ccRCC) (2 cohorts), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
vorolanibtoripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2400094340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094340.